TET2 and acute myeloid leukemia: However, chimeric proteins involving TFs and ERs (e.g. MLL, MYST3, NSD1 ...) may induce a stronger effect than mutations in other TFs and ERs (such as ASXL1, EZH2 or TET2), which may need to co-occur with several other alterations to trigger AML, often after a chronic phase.